# Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole

> **NCT03038308** · PHASE1,PHASE2 · COMPLETED · sponsor: **Columbia University** · enrollment: 16 (actual)

## Conditions studied

- Hyperprolactinemia
- Prolactinoma

## Interventions

- **DRUG:** Ropinirole

## Key facts

- **NCT ID:** NCT03038308
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-16
- **Primary completion:** 2020-11-05
- **Final completion:** 2020-11-05
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2024-06-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03038308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03038308, "Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03038308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*